Literature DB >> 17714081

17Beta-oestradiol partially attenuates the inhibition of nitric oxide synthase-3 by advanced glycation end-products in human platelets.

Lu Chen1, Yuan Liu, Bota Cui, Qiongyu Mi, Yan Huang, Leming Fan, Qi Chen, James Tang, Albert Ferro, Yong Ji.   

Abstract

1. Diabetes mellitus predisposes to and female sex protects against arterial thrombosis. The aim of the present study was to determine whether advanced glycation end-products (AGE), which accumulate in diabetes, impair platelet function through effects on platelet nitric oxide (NO) generation and whether this can be prevented by 17beta-oestradiol. 2. Aggregation responses of human platelet-rich plasma to ADP were determined in the absence or presence of 200 mg/L AGE-modified albumin (AGE-albumin), 10(-5) mol/L 17beta-oestradiol and 10(-5) mol/L ICI 182 780 (the pure oestrogen receptor antagonist). 3. Intraplatelet cGMP, an index of bioactive NO, was measured by radioimmunoassay and expression of nitric oxide synthase (NOS)-3, phosphoserine-1177-NOS-3 and O-glycosylated NOS-3 was quantified by western blotting in response to these same treatments. 4. Advanced glycation end-products-albumin increased platelet aggregatory responses to ADP. This increase was largely prevented by 17beta-oestradiol. Advanced glycation end-products-albumin decreased and 17beta-oestradiol increased intraplatelet NO-attributable cGMP and 17beta-oestradiol attenuated the AGE-albumin-induced decrease in NO-attributable cGMP. Despite no effect on NOS-3 expression, AGE-albumin decreased and 17beta-oestradiol increased phosphoserine-1177-NOS-3 and 17beta-oestradiol largely prevented the decrease in phosphoserine-1177-NOS-3 induced by AGE-albumin. Alone, AGE-albumin increased O-glycosylation of NOS-3 by N-acetylglucosamine, an effect largely inhibited by 17beta-oestradiol. 5. In conclusion, AGE-albumin inhibits platelet NO biosynthesis through effects on serine phosphorylation and O-glycosylation of platelet NOS-3 and this may explain, at least in part, the increase in platelet aggregability induced by AGE-albumin. These effects of AGE-albumin are largely prevented by 17beta-oestradiol. These actions may contribute to the effects of diabetes and sex on arterial thrombosis in vivo.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17714081     DOI: 10.1111/j.1440-1681.2007.04680.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  4 in total

1.  Increased vascular O-GlcNAcylation augments reactivity to constrictor stimuli - VASOACTIVE PEPTIDE SYMPOSIUM.

Authors:  Victor V Lima; Fernanda R C Giachini; Fernando S Carneiro; Zidonia N Carneiro; Zuleica B Fortes; Maria Helena C Carvalho; R Clinton Webb; Rita C Tostes
Journal:  J Am Soc Hypertens       Date:  2008 Nov-Dec

2.  Advanced glycation end products induce a prothrombotic phenotype in mice via interaction with platelet CD36.

Authors:  Weifei Zhu; Wei Li; Roy L Silverstein
Journal:  Blood       Date:  2012-03-19       Impact factor: 22.113

3.  O-GlcNAcylation: a novel post-translational mechanism to alter vascular cellular signaling in health and disease: focus on hypertension.

Authors:  Victor V Lima; Christiné S Rigsby; David M Hardy; R Clinton Webb; Rita C Tostes
Journal:  J Am Soc Hypertens       Date:  2009 Nov-Dec

4.  Impaired vasodilator activity in deoxycorticosterone acetate-salt hypertension is associated with increased protein O-GlcNAcylation.

Authors:  Victor V Lima; Fernanda R C Giachini; Hyehun Choi; Fernando S Carneiro; Zidonia N Carneiro; Zuleica B Fortes; Maria Helena C Carvalho; R Clinton Webb; Rita C Tostes
Journal:  Hypertension       Date:  2009-01-12       Impact factor: 10.190

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.